Navigation Links
Low-dose treatment may block malaria transmission
Date:11/14/2013

Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study published today in Lancet Infectious Diseases by London School of Hygiene & Tropical Medicine researchers.

Primaquine is one of the few antimalarial drugs that targets the transmission stages of the malaria parasite, the gametocytes, and is therefore considered to be an important tool for malaria elimination.

However, standard doses of the drug cause reduced blood count in individuals with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) enzyme. This red blood cell disorder is common in malaria endemic areas, and has therefore limited the use of primaquine in malaria programmes, and prompted the World Health Organization (WHO) to advise a reduction in dosage from 0.75 mg/kg to 0.25mg/kg. But until now, the efficacy of lower doses of primaquine had not been formally evaluated.

The study, carried out in Jinja, Uganda, treated G6PD-normal children with a conventional anti-malarial drug either on its own or with one of three different doses of primaquine. The subsequent carriage of malaria gametocytes was monitored for two weeks and safety outcomes were monitored for four weeks. Results showed that a dose of 0.4 mg/kg, approximately half of the previously recommended dose (0.75 mg/kg), was as effective at reducing the transmission potential of individuals with malaria.

These results establish that low dose primaquine is still effective and safe in a G6PD-normal population, and paves the way for using low-dose primaquine as a component of strategies to reduce malaria transmission and to stop the spread of drug-resistant malaria parasites.

The next step is to include the current WHO-recommended 0.25 mg/kg dose of primaquine in efficacy studies, and to test the safety of low dose primaquine in G6PD-deficient individuals.

Lead author Dr Chi Eziefula, Wellcome Trust clinical research fellow, said: "Until now, the use of primaquine was limited because of safety concerns, but lower doses had never been tested formally. These findings, that efficacy is retained at a lower dose, imply that primaquine could play an important role in malaria elimination programmes. We now need to evaluate the safety of low-dose primaquine in G6PD-deficient individuals. More questions remain to be answered regarding the best operational strategy for the deployment of primaquine to block malaria transmission."

Co-author Professor Chris Drakeley, Director of the London School of Hygiene & Tropical Medicine's Malaria Centre, said: "This work is a crucial step in the evaluation of primaquine as a malaria transmission blocking intervention. Further work is needed to show reduced infectivity to mosquitoes and to confirm the improved safety of these lower doses."

Professor Moses Kamya of the Infectious Disease Research Collaboration in Kampala, Uganda noted: "This study provides important contemporary information that allows malaria control programmes in endemic countries in Africa to consider the use of primaquine as part of their efforts to deal with this killer disease."


'/>"/>

Contact: Katie Steels
press@lshtm.ac.uk
44-020-792-92802
London School of Hygiene & Tropical Medicine
Source:Eurekalert

Related biology news :

1. Northeastern researchers have discovered a new treatment to cure MRSA infection
2. Wayne State researchers discover specific inhibitor for rheumatoid arthritis treatment
3. Discovery may lead to new treatments for allergic diseases
4. Research reveals new understanding, warning signs, and potential treatments for multiple sclerosis
5. Genetic aberration paves the way for new treatment of cancer disease
6. Breakthrough by Temple researchers could lead to new treatment for heart attack
7. Queens University in €6m bid to find new Cystic Fibrosis treatments
8. BUSM researchers identify molecule that could aid lung cancer detection, treatment
9. Salvianolate for treatment of cerebral ischemia-reperfusion injuries
10. UAlberta medical researchers discover potential new treatment for colitis
11. New eye treatment effective in laboratory tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: